Phase i trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl + hematological malignancies

Prithviraj Bose, Edward B. Perkins, Connie Honeycut, Martha D. Wellons, Tammy Stefan, James W. Jacobberger, Emmanouil Kontopodis, Jan H. Beumer, Merrill J. Egorin, Chiyo Imamura, W. Douglas Figg, Judith E. Karp, Omer N. Koc, Brenda W. Cooper, Selina M. Luger, A. Dimitrios Colevas, John D. Roberts, Steven Grant

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl + malignancies. Methods: In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1 h intravenous infusion weekly for 3 weeks every 4 weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome- positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. Results: A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30 months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. Conclusions: This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.

Original languageEnglish
Pages (from-to)1657-1667
Number of pages11
JournalCancer Chemotherapy and Pharmacology
Volume69
Issue number6
DOIs
Publication statusPublished - 2012 Jun

Fingerprint

alvocidib
Hematologic Neoplasms
bcr-abl Fusion Proteins
Pharmacokinetics
Cyclin-Dependent Kinases
Pharmacodynamics
Apoptosis Regulatory Proteins
Transcription
Chromosomes
Philadelphia Chromosome
Protein-Tyrosine Kinases
Imatinib Mesylate
Bone
Blood
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intravenous Infusions
Apoptosis

Keywords

  • Alvocidib
  • Bcr-Abl
  • CDK inhibitor
  • Cyclin-dependent kinase inhibitor
  • Flavopiridol
  • Imatinib
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Phase i trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl + hematological malignancies. / Bose, Prithviraj; Perkins, Edward B.; Honeycut, Connie; Wellons, Martha D.; Stefan, Tammy; Jacobberger, James W.; Kontopodis, Emmanouil; Beumer, Jan H.; Egorin, Merrill J.; Imamura, Chiyo; Figg, W. Douglas; Karp, Judith E.; Koc, Omer N.; Cooper, Brenda W.; Luger, Selina M.; Colevas, A. Dimitrios; Roberts, John D.; Grant, Steven.

In: Cancer Chemotherapy and Pharmacology, Vol. 69, No. 6, 06.2012, p. 1657-1667.

Research output: Contribution to journalArticle

Bose, P, Perkins, EB, Honeycut, C, Wellons, MD, Stefan, T, Jacobberger, JW, Kontopodis, E, Beumer, JH, Egorin, MJ, Imamura, C, Figg, WD, Karp, JE, Koc, ON, Cooper, BW, Luger, SM, Colevas, AD, Roberts, JD & Grant, S 2012, 'Phase i trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl + hematological malignancies', Cancer Chemotherapy and Pharmacology, vol. 69, no. 6, pp. 1657-1667. https://doi.org/10.1007/s00280-012-1839-5
Bose, Prithviraj ; Perkins, Edward B. ; Honeycut, Connie ; Wellons, Martha D. ; Stefan, Tammy ; Jacobberger, James W. ; Kontopodis, Emmanouil ; Beumer, Jan H. ; Egorin, Merrill J. ; Imamura, Chiyo ; Figg, W. Douglas ; Karp, Judith E. ; Koc, Omer N. ; Cooper, Brenda W. ; Luger, Selina M. ; Colevas, A. Dimitrios ; Roberts, John D. ; Grant, Steven. / Phase i trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl + hematological malignancies. In: Cancer Chemotherapy and Pharmacology. 2012 ; Vol. 69, No. 6. pp. 1657-1667.
@article{e87edbb3790a43fa84db396555034950,
title = "Phase i trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl + hematological malignancies",
abstract = "Purpose: Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl + malignancies. Methods: In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1 h intravenous infusion weekly for 3 weeks every 4 weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome- positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. Results: A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30 months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. Conclusions: This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.",
keywords = "Alvocidib, Bcr-Abl, CDK inhibitor, Cyclin-dependent kinase inhibitor, Flavopiridol, Imatinib, Tyrosine kinase inhibitor",
author = "Prithviraj Bose and Perkins, {Edward B.} and Connie Honeycut and Wellons, {Martha D.} and Tammy Stefan and Jacobberger, {James W.} and Emmanouil Kontopodis and Beumer, {Jan H.} and Egorin, {Merrill J.} and Chiyo Imamura and Figg, {W. Douglas} and Karp, {Judith E.} and Koc, {Omer N.} and Cooper, {Brenda W.} and Luger, {Selina M.} and Colevas, {A. Dimitrios} and Roberts, {John D.} and Steven Grant",
year = "2012",
month = "6",
doi = "10.1007/s00280-012-1839-5",
language = "English",
volume = "69",
pages = "1657--1667",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Phase i trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl + hematological malignancies

AU - Bose, Prithviraj

AU - Perkins, Edward B.

AU - Honeycut, Connie

AU - Wellons, Martha D.

AU - Stefan, Tammy

AU - Jacobberger, James W.

AU - Kontopodis, Emmanouil

AU - Beumer, Jan H.

AU - Egorin, Merrill J.

AU - Imamura, Chiyo

AU - Figg, W. Douglas

AU - Karp, Judith E.

AU - Koc, Omer N.

AU - Cooper, Brenda W.

AU - Luger, Selina M.

AU - Colevas, A. Dimitrios

AU - Roberts, John D.

AU - Grant, Steven

PY - 2012/6

Y1 - 2012/6

N2 - Purpose: Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl + malignancies. Methods: In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1 h intravenous infusion weekly for 3 weeks every 4 weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome- positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. Results: A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30 months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. Conclusions: This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.

AB - Purpose: Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl + malignancies. Methods: In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1 h intravenous infusion weekly for 3 weeks every 4 weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome- positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. Results: A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30 months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. Conclusions: This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.

KW - Alvocidib

KW - Bcr-Abl

KW - CDK inhibitor

KW - Cyclin-dependent kinase inhibitor

KW - Flavopiridol

KW - Imatinib

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84863806046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863806046&partnerID=8YFLogxK

U2 - 10.1007/s00280-012-1839-5

DO - 10.1007/s00280-012-1839-5

M3 - Article

C2 - 22349810

AN - SCOPUS:84863806046

VL - 69

SP - 1657

EP - 1667

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -